Protagonist Therapeutics Inc (PTGX)
Return on equity (ROE)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | 275,188 | 170,849 | 169,954 | 162,110 | -76,659 | -135,279 | -131,335 | -133,506 | -122,826 | -128,448 | -132,091 | -122,302 | -125,551 | -107,530 | -81,489 | -70,068 | -66,150 | -64,765 | -73,411 | -83,164 |
| Total stockholders’ equity | US$ in thousands | 675,295 | 531,915 | 541,324 | 560,444 | 336,677 | -643,045 | 294,068 | -570,480 | -536,755 | 243,616 | 267,978 | 301,778 | -409,362 | 329,660 | 357,447 | 259,334 | -283,811 | 169,590 | 167,485 | 62,666 |
| ROE | 40.75% | 32.12% | 31.40% | 28.93% | -22.77% | — | -44.66% | — | — | -52.73% | -49.29% | -40.53% | — | -32.62% | -22.80% | -27.02% | — | -38.19% | -43.83% | -132.71% |
December 31, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $275,188K ÷ $675,295K
= 40.75%
Protagonist Therapeutics Inc's return on equity (ROE) has exhibited significant fluctuations over the past few years. Beginning in March 2020 with a negative ROE of -132.71%, the company showed improvements in subsequent quarters but remained in negative territory until the end of March 2024.
The negative ROE figures indicate that during these periods, Protagonist Therapeutics Inc was generating net losses, relative to its shareholders' equity. This may suggest inefficiencies in the company's operations, high expenses, or other financial challenges affecting its profitability.
However, starting in March 2024, the company saw a notable turnaround, achieving a positive ROE of 28.93%, followed by further increases reaching 40.75% by the end of December 2024. These positive ROE figures indicate that Protagonist Therapeutics Inc was able to generate profits exceeding the amount of shareholder equity invested, reflecting better financial performance and efficiency.
Overall, the recent trend of improving ROE suggests that Protagonist Therapeutics Inc has made positive strides in enhancing its financial performance and generating returns for its shareholders. Continued monitoring of the ROE will be crucial in assessing the company's ongoing profitability and value creation.
Peer comparison
Dec 31, 2024